CA‐549: A new tumor marker for patients with advanced breast cancer

Laurence Demers, Harold Harvey, Jerry D. Glenn, Pramod K. Gaur

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A murine monoclonal antibody, BC4E 549, an IgG1 adapted as tracer antibody in a sandwich immunoradiometric assay, was used to detect a circulating breast cancer‐associated antigen, CA‐549, in patients with advanced breast cancer. The study was designed to examine the specificity and sensitivity of CA‐549 measurements as a specific circulating marker for breast cancer. In a population of 100 normal pre‐and postmenopausal women, serum levels ranged from 1–10 μ/ml. In contrast, 38 of 46 patients (83%) with active, advanced‐stage breast cancer had circulating levels in excess of 10 μ/ml, and levels in several patients exceeded 100 μ/ml. Patients on adjuvant therapy with breast cancer in remission, patients with benign breast disease, and patients with cancers of other sites such as colorectal, ovarian, and lung cancer did not show significant elevations (>10 μ/ml, P > 0.001) of this circulating antigen. Measurement of this breast cancer associated antigen may be of use in the evaluation of treatment for patients with advanced stage breast cancer.

Original languageEnglish (US)
Pages (from-to)168-173
Number of pages6
JournalJournal of Clinical Laboratory Analysis
Volume2
Issue number3
DOIs
StatePublished - Jan 1 1988

Fingerprint

Tumor Biomarkers
Breast Neoplasms
Antigens
Assays
Immunoglobulin G
Monoclonal Antibodies
Antibodies
Immunoradiometric Assay
Breast Diseases
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Breast
Sensitivity and Specificity
Therapeutics
Serum
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Clinical Biochemistry
  • Medical Laboratory Technology
  • Biochemistry, medical
  • Microbiology (medical)

Cite this

Demers, Laurence ; Harvey, Harold ; Glenn, Jerry D. ; Gaur, Pramod K. / CA‐549 : A new tumor marker for patients with advanced breast cancer. In: Journal of Clinical Laboratory Analysis. 1988 ; Vol. 2, No. 3. pp. 168-173.
@article{077e6e4982014f13a79a9a00ff698804,
title = "CA‐549: A new tumor marker for patients with advanced breast cancer",
abstract = "A murine monoclonal antibody, BC4E 549, an IgG1 adapted as tracer antibody in a sandwich immunoradiometric assay, was used to detect a circulating breast cancer‐associated antigen, CA‐549, in patients with advanced breast cancer. The study was designed to examine the specificity and sensitivity of CA‐549 measurements as a specific circulating marker for breast cancer. In a population of 100 normal pre‐and postmenopausal women, serum levels ranged from 1–10 μ/ml. In contrast, 38 of 46 patients (83{\%}) with active, advanced‐stage breast cancer had circulating levels in excess of 10 μ/ml, and levels in several patients exceeded 100 μ/ml. Patients on adjuvant therapy with breast cancer in remission, patients with benign breast disease, and patients with cancers of other sites such as colorectal, ovarian, and lung cancer did not show significant elevations (>10 μ/ml, P > 0.001) of this circulating antigen. Measurement of this breast cancer associated antigen may be of use in the evaluation of treatment for patients with advanced stage breast cancer.",
author = "Laurence Demers and Harold Harvey and Glenn, {Jerry D.} and Gaur, {Pramod K.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1002/jcla.1860020309",
language = "English (US)",
volume = "2",
pages = "168--173",
journal = "Journal of Clinical Laboratory Analysis",
issn = "0887-8013",
publisher = "Wiley-Liss Inc.",
number = "3",

}

CA‐549 : A new tumor marker for patients with advanced breast cancer. / Demers, Laurence; Harvey, Harold; Glenn, Jerry D.; Gaur, Pramod K.

In: Journal of Clinical Laboratory Analysis, Vol. 2, No. 3, 01.01.1988, p. 168-173.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CA‐549

T2 - A new tumor marker for patients with advanced breast cancer

AU - Demers, Laurence

AU - Harvey, Harold

AU - Glenn, Jerry D.

AU - Gaur, Pramod K.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - A murine monoclonal antibody, BC4E 549, an IgG1 adapted as tracer antibody in a sandwich immunoradiometric assay, was used to detect a circulating breast cancer‐associated antigen, CA‐549, in patients with advanced breast cancer. The study was designed to examine the specificity and sensitivity of CA‐549 measurements as a specific circulating marker for breast cancer. In a population of 100 normal pre‐and postmenopausal women, serum levels ranged from 1–10 μ/ml. In contrast, 38 of 46 patients (83%) with active, advanced‐stage breast cancer had circulating levels in excess of 10 μ/ml, and levels in several patients exceeded 100 μ/ml. Patients on adjuvant therapy with breast cancer in remission, patients with benign breast disease, and patients with cancers of other sites such as colorectal, ovarian, and lung cancer did not show significant elevations (>10 μ/ml, P > 0.001) of this circulating antigen. Measurement of this breast cancer associated antigen may be of use in the evaluation of treatment for patients with advanced stage breast cancer.

AB - A murine monoclonal antibody, BC4E 549, an IgG1 adapted as tracer antibody in a sandwich immunoradiometric assay, was used to detect a circulating breast cancer‐associated antigen, CA‐549, in patients with advanced breast cancer. The study was designed to examine the specificity and sensitivity of CA‐549 measurements as a specific circulating marker for breast cancer. In a population of 100 normal pre‐and postmenopausal women, serum levels ranged from 1–10 μ/ml. In contrast, 38 of 46 patients (83%) with active, advanced‐stage breast cancer had circulating levels in excess of 10 μ/ml, and levels in several patients exceeded 100 μ/ml. Patients on adjuvant therapy with breast cancer in remission, patients with benign breast disease, and patients with cancers of other sites such as colorectal, ovarian, and lung cancer did not show significant elevations (>10 μ/ml, P > 0.001) of this circulating antigen. Measurement of this breast cancer associated antigen may be of use in the evaluation of treatment for patients with advanced stage breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84966154708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966154708&partnerID=8YFLogxK

U2 - 10.1002/jcla.1860020309

DO - 10.1002/jcla.1860020309

M3 - Article

AN - SCOPUS:84966154708

VL - 2

SP - 168

EP - 173

JO - Journal of Clinical Laboratory Analysis

JF - Journal of Clinical Laboratory Analysis

SN - 0887-8013

IS - 3

ER -